Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels
WHEN: Wednesday, 13th April, noon-1pm
The detection of cancer in the body, particularly early in its progression, can provide life-saving information for subsequent treatment. Researchers are now demonstrating that increases in the speed, accuracy, and resolution of next-generation sequencing (NGS) have made it possible to sequence minute amounts of DNA from scarce and rare samples, such as circulating cancer cells from liquid biopsies or archival tissue in formalin-fixed paraffin embedded (FFPE) samples. Taking this to the next level, NGS panels enable targeted sequencing of a small number of cancer-specific genes that can aid in quickly identifying and categorizing a particular cancer. This seminar will focus on the development and use of cancer detection panels for FFPE/liquid biopsy samples. Relying on their experience in both research and clinical settings, our panelists will discuss the challenges of designing, developing, analytically validating, and employing targeted NGS panels in translational research laboratories. The dramatic potential for future applications of NGS panels in a clinical setting will also be discussed.
During the webinar, our speakers will:
- Explain the importance and utility of applying NGS for the characterization of tumors
- Highlight the hurdles encountered when developing NGS cancer panels, including sensitivity and reproducibility
- Describe their successes in analyzing tumor samples in their research
- Answer your questions live during the broadcast!
Participants:
P. Mickey Williams, Ph.D.
Frederick National Laboratory
for Cancer Research
Frederick, MD
Jeremy Segal, M.D., Ph.D.
University of Chicago Medicine
Chicago, IL